by | Apr 16, 2024 | Uncategorized
An FDA advisory committee unanimously voted minimal residual disease should be an accepted endpoint for accelerated approval of clinical trials investigating treatments for patients with multiple myeloma.PFS and OS are the current endpoints in multiple myeloma trials,...
by | Apr 8, 2024 | Uncategorized
The FDA approved ciltacabtagene autoleucel for earlier use in certain adults with relapsed or refractory multiple myeloma.The expanded indication permits treatment with the chimeric antigen receptor T cells after first relapse and applies to adults who are refractory...
by | Apr 8, 2024 | Uncategorized
Source: CureToday articles The Food and Drug Administration approved the CAR-T cell therapy, Carvykti, for previously treated patients with multiple myeloma. Read More
by | Apr 5, 2024 | Uncategorized
The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a company release.This approval expands the indication for idecabtagene...
by | Apr 5, 2024 | Uncategorized
Source: CureToday articles The Food and Drug Administration approved Abecma for adults with relapsed or refractory multiple myeloma who have received two or more previous lines of therapy. Read More
by | Apr 3, 2024 | Uncategorized
Source: CureToday articles There is no difference in treatment for non-secretory multiple myeloma and multiple myeloma, an expert told CURE®. Read More
